These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

998 related items for PubMed ID: 27912779

  • 1. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 2. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Chen X.
    Arch Gynecol Obstet; 2017 Feb 02; 295(2):451-458. PubMed ID: 27913927
    [Abstract] [Full Text] [Related]

  • 3. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J, Liu N, Zhang A, Bao X.
    J Obstet Gynaecol Res; 2018 Sep 02; 44(9):1808-1816. PubMed ID: 30019801
    [Abstract] [Full Text] [Related]

  • 4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 02; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 5. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.
    Ann Surg Oncol; 2014 Feb 02; 21(2):629-36. PubMed ID: 24052318
    [Abstract] [Full Text] [Related]

  • 6. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H, Maurer KA, Nutter B, Rose PG.
    Int J Gynecol Cancer; 2015 Jun 02; 25(5):823-9. PubMed ID: 25828750
    [Abstract] [Full Text] [Related]

  • 7. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y, Li L.
    Tumour Biol; 2016 Nov 11; 37(11):14765-14772. PubMed ID: 27629144
    [Abstract] [Full Text] [Related]

  • 13. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    Am J Obstet Gynecol; 2017 Sep 11; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [Abstract] [Full Text] [Related]

  • 14. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A, Bodnar L, Wcisło GB, Jerzak MM, Szczylik C, Baranowski W.
    Ginekol Pol; 2008 Feb 11; 79(2):108-14. PubMed ID: 18510089
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, Guimarães AP, Achatz MI.
    Ann Surg Oncol; 2015 Dec 11; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec 11; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
    Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A.
    Ann Surg Oncol; 2015 Dec 11; 22 Suppl 3():S952-8. PubMed ID: 26036187
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.